Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics
July 28, 2015 9:23 AM EDTCanaccord Genuity maintained a Hold rating on Teva Pharma (NYSE: TEVA), and raised the price target to $79.00 (from $63.00), following the announced acquisition of Allergan Generics for $40.5B - $33.75B in cash and $6.75B in stock. Analyst Corey Davis said that this is not a good signal about the overall future of the... More
Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO
July 28, 2015 8:12 AM EDTLeerink Partners reiterated an Outperform rating on Teva Pharma (NYSE: TEVA), and raised the price target to $84.00 (from $74.00), following a call with CFO Eyal Desheh. The TEVA-AGN deal is estimated to close in 1Q'16 and management still anticipates holding its annual guidance... More
Mylan's (MYL) Price Target Reduced to $65 at Deutsche Bank
July 27, 2015 2:34 PM EDTDeutsche Bank maintained a Buy rating on Mylan (NASDAQ: MYL) but cut its price target to $65.00 (from $82.00). The change reflects standalone valuation after Teva Pharma (NYSE: TEVA) earlier withdrew its agreement to acquired the company.
"Following TEVAs announced plan to acquire Allergan... More
Teva Pharma (TEVA) PT Raised to $74 at Maxim Group on Deal for Allergan's Generic Drug Business
July 27, 2015 11:10 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating and raised his price target on Teva Pharma (NYSE: TEVA) to $74.00 (from $64.00) after the company agreed to acquire Allergan's legacy Actavis global generics business. The company is dropping its bid for... More
Cowen Downgrades Mylan (MYL) to Market Perform
July 27, 2015 7:50 AM EDTCowen downgraded Mylan (NASDAQ: MYL) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.
Shares of Mylan closed at $65.94 yesterday.
... MoreMylan (MYL) Comments on Teva/Allergan Deal; Strategic Focus Remains Unchanged
July 27, 2015 6:43 AM EDTMylan (Nasdaq: MYL) issued the following statement regarding Teva's (NYSE: TEVA) announcement of its entry into an agreement to acquire Allergan's (NYSE: AGN) Generic Drug Unit and its withdrawal of its unsolicited expression of interest to acquire Mylan.
Mylan... More
